Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of TMC649128 alone and with pegylated interferon alfa-2a plus ribavirin in genotype 1 hepatitis C
NL-OMON35874Phase 1Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMC-649128 in hepatitis C virus infection (8 arms), sponsored by PRA Health Sciences. Primary endpoints: HCV RNA levels, Intracellular triphosphate concentration (TMC652337) in PBMCs and 13 more. Started Jul 2011; status: active, not recruiting.
02
Drugs
TMC-649128
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON35874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35874.